News
ALT
7.19
+1.70%
0.12
ALTIMMUNE TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON MAY 9, 2024
Reuters · 18h ago
Altimmune to Participate at Two Upcoming Conferences
Barchart · 1d ago
Peering Into Altimmune's Recent Short Interest
Altimmune's short percent of float has risen 41.55% since its last report. The company has 17.73 million shares sold short, which is 25.21% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-3M, Phibro Animal Health, copper miners
Dow Jones Industrial Average was up 0.32% in volatile trading on Monday. Shares of Tesla and Apple advanced. Investors exercised caution ahead of the Federal Reserve's interest rate decision later in the week. The top three S&P 500 percentage gainers were Tesla, Apple and Domino's Pizza.
Reuters · 3d ago
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Clever Leaves Holdings Inc. Shares dipped 60% to $1.6498 on Monday. The company announced it will voluntarily delist its common shares from the Nasdaq. Shares of Deciphera Pharmaceuticals, Inc. Climbed 73% in today's mid-day session.
Benzinga · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-Revvity, Southern Co, Duke Energy
Wall Street's main indexes crept higher in volatile trading on Monday. Shares of Tesla and Apple advanced. Investors exercised caution ahead of the Federal Reserve's interest rate decision later in the week. Revvity, Southern Co, Duke Energy were among the stocks on the move. The Dow Jones Industrial Average was up 0.20% in early trading.
Reuters · 3d ago
ALTIMMUNE SHARES DOWN 7% AFTER GUGGENHEIM CUTS TO NEUTRAL FROM BUY
Reuters · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-Fulton, Deciphera Pharmaceuticals, VivoPower
U.S. Stocks were poised for a higher open on Monday. Tesla and Apple led gains in megacap companies. Investors exercised caution ahead of the Federal Reserve's interest rate decision later in the week. Dow e-minis were up 0.14% in early trading.
Reuters · 3d ago
BUZZ-Guggenheim downgrades Altimmune as 'ship has likely sailed' for obesity drug
Shares of drug developer Altimmune fall 5.8% to $6.84 premarket. Brokerage Guggenheim downgrades stock to 'buy' from 'buy', removes PT on the stock. Says 'ship has likely sailed' for obesity drug pemvidutide.
Reuters · 3d ago
Deutsche Bank, Daqo New Energy And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Shares of Deutsche Bank Aktiengesellschaft fell sharply in today's pre-market trading. The company estimates it could have to pay up to €1.3 billion related to its Postbank litigation. The Dow futures were higher this morning, with the Dow futures gaining over 50 points.
Benzinga · 3d ago
ALT, CYCC and DB among pre-market losers
On the Move ALT, CYCC and DB among pre-market losers. Clever Leaves Holdings (CLVR) announces Voluntary Delisting and SEC Deregistration. Addex Therapeutics Ltd (ADXN) provides update on phase 2 Epilepsy study.
Seeking Alpha · 3d ago
Altimmune Cut to Neutral From Buy by Guggenheim
Dow Jones · 3d ago
Weekly Report: what happened at ALT last week (0422-0426)?
Weekly Report · 3d ago
Guggenheim Downgrades Altimmune to Neutral
Benzinga · 3d ago
ALTIMMUNE INC <ALT.O>: GUGGENHEIM CUTS TO NEUTRAL FROM BUY
Reuters · 3d ago
Roche: Value Remains Despite Covid-19 Revenue Growth Loss
Roche has good long-term prospects despite Covid-19 revenue growth loss. Vabysmo and Phesgo are still strong growth drivers for the company going forward. Ocrevus is expected to remain as the best-selling Multiple Sclerosis Drug in 2030. The company has established a huge acquisition for drugs for the obesity drugs market.
Seeking Alpha · 4d ago
ALT January 2026 Options Begin Trading
NASDAQ · 6d ago
Altimmune Statement on the Passing of Dr. Stephen Harrison
Barchart · 04/25 16:24
3 Potential Biopharma Buyout Targets
Recent lack of M&A activity and rising interest rates have led to a 20% decline in small-cap biotech equities. Big Pharma's surplus of cash and key patent expirations should lead to increased M& a volume in the coming year. Three promising small biopharma names are attractive as standalone entities but would make logical buyout targets. Mirum Pharmaceuticals, Inc., ImmunoGen, Inc. And GLP-1 are three names that could be attractive.
Seeking Alpha · 04/23 17:12
Weekly Report: what happened at ALT last week (0415-0419)?
Weekly Report · 04/22 10:43
More
Webull provides a variety of real-time ALT stock news. You can receive the latest news about Altimmune through multiple platforms. This information may help you make smarter investment decisions.
About ALT
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.